MedTrace Logo

Long Term Metabolic Safety of Norditropin® Treatment of Small for Gestational Age (SGA) Subjects

NCT00787878 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 153

Last updated 2017-01-18

No results posted yet for this study

Summary

The study is conducted in Europe. The primary aim of this observational study is to compare the insulin sensitivity in small for gestational age (SGA) subjects treated with Norditropin® with untreated small for gestational age (SGA) subjects and with average for gestational age (AGA) subjects.

Conditions

  • Foetal Growth Problem
  • Small for Gestational Age

Interventions

DRUG

somatropin

SGA previously treated with Norditropin®

DRUG

No treatment given

Untreated SGA

DRUG

No treatment given

AGA (Average gestational age)

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Min Age
18 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00787878 on ClinicalTrials.gov